Last reviewed · How we verify
AML Y mg
AML Y mg is an anti-CD28 monoclonal antibody that inhibits T-cell activation.
AML Y mg is an anti-CD28 monoclonal antibody that inhibits T-cell activation. Used for Treatment of relapsed or refractory follicular lymphoma.
At a glance
| Generic name | AML Y mg |
|---|---|
| Sponsor | Celltrion |
| Drug class | anti-CD28 monoclonal antibody |
| Target | CD28 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to CD28, AML Y mg prevents the interaction between CD28 and its ligands, thereby inhibiting the activation of T-cells. This mechanism of action is thought to reduce inflammation and modulate the immune response.
Approved indications
- Treatment of relapsed or refractory follicular lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects (PHASE3)
- Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |